Medpace Holdings, Inc. is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.
Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services. The company also provides specialized support for areas such as imaging, bioanalytical testing and clinical trial logistics. Its work spans multiple therapeutic areas, including oncology, cardiology, central nervous system disorders, metabolic disease, infectious disease and medical devices.
Headquartered in Cincinnati, Ohio, Medpace conducts and supports studies through operations serving North America, Europe, Asia-Pacific and other international markets. The company was founded in 1992 by August J. Troendle, who serves as its chairman and chief executive officer. Medpace Holdings became a publicly traded company on the Nasdaq under the symbol MEDP in 2016.
AI Generated. May Contain Errors.
